Evidence map›Paper›PMID 41438873›Full record

ArticleMolecular therapy. Methods & clinical development2025

Targeted inhibition of

Betül Findik, Benjamin Dannenmann, Franka Bernhard, Masako Monika Kaufmann, Sandra Ammann, Sergey Kandabarau, Maksim Klimiankou, Fabian Mauch, Patrick Münzer, Oliver Borst and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Betül FindikDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Benjamin DannenmannDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Franka BernhardDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Masako Monika KaufmannInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg, Germany.
Sandra AmmannInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg, Germany.
Sergey KandabarauDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Maksim KlimiankouDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Fabian MauchDFG Heisenberg Group Cardiovascular Thromboinflammation and Translational Thrombocardiology, University of Tübingen, Tübingen, Germany.
Patrick MünzerDFG Heisenberg Group Cardiovascular Thromboinflammation and Translational Thrombocardiology, University of Tübingen, Tübingen, Germany.
Oliver BorstDFG Heisenberg Group Cardiovascular Thromboinflammation and Translational Thrombocardiology, University of Tübingen, Tübingen, Germany.
Isabel KlefenzDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Doris SteinemannDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Claudia LengerkeDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Cornelia ZeidlerDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Toni CathomenInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg, Germany.
Karl WelteSevere Chronic Neutropenia International Registry, SCNIR, Hannover, Germany.
Masoud NasriDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Julia SkokowaDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.

Funding

Severe Chronic Neutropenia International RegistryR24AI162637 · BOSTON CHILDREN'S HOSPITAL · 2025 to 2025
$1.1M
Severe Chronic Neutropenia International RegistryR24AI049393 · UNIVERSITY OF WASHINGTON · 2004 to 2005
$856k
NIAID NIH HHS R24 AI049393NIAID NIH HHS R24 AI162637
6 · The paper itself

Abstract

Autosomal dominant mutations in

Indexed as

adenine base editingbone marrow failure syndromeELANEgene therapyhemopoietic stem cellsNETsneutrophil elastaseneutrophilspre-leukemiasevere congenital neutropenia

Identifiers

PMID41438873
PMCPMC12719991

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.